Literature DB >> 8755929

Molecular analysis of chromosome 9q deletions in two Gorlin syndrome patients.

R Shimkets1, M R Gailani, V M Siu, T Yang-Feng, C L Pressman, S Levanat, A Goldstein, M Dean, A E Bale.   

Abstract

Gorlin syndrome is an autosomal dominant disorder characterized by multiple basal cell carcinomas, medulloblastomas, ovarian fibromas, and a variety of developmental defects. All affected individuals share certain key features, but there is significant phenotypic variability within and among kindreds with respect to malformations. The gene (NBCCS) maps to chromosome 9q22, and allelic loss at this location is common in tumors from Gorlin syndrome patients. Two recessive cancer-predisposition syndromes, xeroderma pigmentosum group A (XPAC) and Fanconi anemia group C (FACC), map to the NBCCS region; and unusual, dominant mutations in these genes have been proposed as the cause of Gorlin syndrome. This study presents cytogenetic and molecular characterization of germ-line deletions in one patient with a chromosome 9q22 deletion and in a second patient with a deletion of 9q22-q3l. Both have typical features of Gorlin syndrome plus additional findings, including mental retardation, conductive hearing loss, and failure to thrive. That Gorlin syndrome can be caused by null mutations (deletions) rather than by activating mutations has several implications. First, in conjunction with previous analyses of allelic loss in tumors, this study provides evidence that associated neoplasms arise with homozygous inactivation of the gene. In addition, dominant mutations of the XPAC and FACC1 genes can be ruled out as the cause of Gorlin syndrome, since the two patients described have null mutations. Finally, phenotypic features that show variable expression must be influenced by genetic background, epigenetic effects, somatic mutations, or environmental factors, since these two patients with identical alterations (deletions) of the Gorlin syndrome gene have somewhat different manifestations of Gorlin syndrome.

Entities:  

Mesh:

Year:  1996        PMID: 8755929      PMCID: PMC1914731     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome.

Authors:  R J GORLIN; R W GOLTZ
Journal:  N Engl J Med       Date:  1960-05-05       Impact factor: 91.245

2.  The basal-cell nevus: its relationship to multiple cutaneous cancers and associated anomalies of development.

Authors:  J B HOWELL; M R CARO
Journal:  AMA Arch Derm       Date:  1959-01

3.  Report and abstracts of the 4th International Workshop on Chromosome 9. Williamsburg, Virginia, USA, April 23-25, 1995.

Authors: 
Journal:  Ann Hum Genet       Date:  1995-10       Impact factor: 1.670

4.  A two-hit model for developmental defects in Gorlin syndrome.

Authors:  S Levanat; R J Gorlin; S Fallet; D R Johnson; J E Fantasia; A E Bale
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

5.  Prenatal diagnosis of Gorlin syndrome.

Authors:  M G Bialer; M R Gailani; J A McLaughlin; B Petrikovsky; A E Bale
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321

6.  Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin.

Authors:  A G Quinn; C Campbell; E Healy; J L Rees
Journal:  J Invest Dermatol       Date:  1994-03       Impact factor: 8.551

Review 7.  Nevoid basal cell carcinoma syndrome.

Authors:  A E Bale; M R Gailani; D J Leffell
Journal:  J Invest Dermatol       Date:  1994-11       Impact factor: 8.551

8.  Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas.

Authors:  S M Shanley; H Dawkins; B J Wainwright; C Wicking; P Heenan; M Eldon; J Searle; G Chenevix-Trench
Journal:  Hum Mol Genet       Date:  1995-01       Impact factor: 6.150

Review 9.  Nevoid basal cell carcinoma syndrome.

Authors:  R J Gorlin
Journal:  Dermatol Clin       Date:  1995-01       Impact factor: 3.478

10.  Parental origin of chromosome 9q22.3-q31 lost in basal cell carcinomas from basal cell nevus syndrome patients.

Authors:  J M Bonifas; J W Bare; R L Kerschmann; S P Master; E H Epstein
Journal:  Hum Mol Genet       Date:  1994-03       Impact factor: 6.150

View more
  12 in total

1.  9q22 Deletion--first familial case.

Authors:  Linda Siggberg; Maarit Peippo; Marjatta Sipponen; Taina Miikkulainen; Keiko Shimojima; Toshiyuki Yamamoto; Jaakko Ignatius; Sakari Knuutila
Journal:  Orphanet J Rare Dis       Date:  2011-06-22       Impact factor: 4.123

2.  Variable expressivity of patched mutations in flies and humans.

Authors:  A E Bale
Journal:  Am J Hum Genet       Date:  1997-01       Impact factor: 11.025

Review 3.  Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms.

Authors:  Chi Young Ok; Rajesh Ramachandra Singh; Francisco Vega
Journal:  Am J Pathol       Date:  2011-11-01       Impact factor: 4.307

4.  Copy number variations and cancer.

Authors:  Adam Shlien; David Malkin
Journal:  Genome Med       Date:  2009-06-16       Impact factor: 11.117

5.  Interstitial deletion of chromosome 9, int del(9)(9q22.31-q31.2), including the genes causing multiple basal cell nevus syndrome and Robinow/brachydactyly 1 syndrome.

Authors:  Carla Olivieri; Paola Maraschio; Desiree Caselli; Carla Martini; Giampiero Beluffi; Emanuela Maserati; Cesare Danesino
Journal:  Eur J Pediatr       Date:  2002-12-10       Impact factor: 3.183

6.  High-density oligonucleotide array with sub-kilobase resolution reveals breakpoint information of submicroscopic deletions in nevoid basal cell carcinoma syndrome.

Authors:  Katsunori Fujii; Shumpei Ishikawa; Hideki Uchikawa; Daisuke Komura; Michael H Shapero; Fan Shen; Jing Hung; Hiroshi Arai; Yoko Tanaka; Kimio Sasaki; Yoichi Kohno; Masao Yamada; Keith W Jones; Hiroyuki Aburatani; Toshiyuki Miyashita
Journal:  Hum Genet       Date:  2007-08-17       Impact factor: 4.132

7.  PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study.

Authors:  N Soufir; B Gerard; M Portela; A Brice; M Liboutet; P Saiag; V Descamps; D Kerob; P Wolkenstein; I Gorin; C Lebbe; N Dupin; B Crickx; N Basset-Seguin; B Grandchamp
Journal:  Br J Cancer       Date:  2006-08-21       Impact factor: 7.640

8.  Identification of rare germline copy number variations over-represented in five human cancer types.

Authors:  Richard W Park; Tae-Min Kim; Simon Kasif; Peter J Park
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

Review 9.  Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.

Authors:  Patrick Booms; Marc Harth; Robert Sader; Shahram Ghanaati
Journal:  Ann Maxillofac Surg       Date:  2015 Jan-Jun

10.  Comparative genomic analysis of intracranial germ cell tumors - the preliminary study focused on Sonic Hedgehog signaling pathway.

Authors:  Dominika Kuleszo; Magdalena Koczkowska; Beata S Lipska-Ziętkiewicz; Wiesława Grajkowska; Elżbieta Adamkiewicz-Drożyńska; Bożenna Dembowska-Bagińska; Maciej Ciołkowski; Ewa Iżycka-Świeszewska
Journal:  Contemp Oncol (Pozn)       Date:  2017-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.